Brentuximab vedotin

Abstract

Neutropenia and off label use: case report In a case series of 3 children, who were diagnosed with ALK positive anaplastic large cell lymphoma (ALCL) in between 2013 to 2019 , a child [sex and exact age not stated] developed neutropenia during off-label treatment with brentuximab vedotin for early relapse of ALCL. The child, with ALK ALCL, received chemotherapy as per ALCL99 and was in remission when therapy was completed. However, the child developed early relapse of ALCL. Thus, off-label brentuximab vedotin was initiated [dosage and route not stated]. The child achieved complete remission after 2 doses of brentuximab vedotin. After an additional dose to bridge to transplant, the child received a allogeneic hematopoietic stem cell transplantation. However, the child developed grade IV neutropenia secondary to offlabel brentuximab vedotin [time to reaction onset and outcome not stated].